Johnson & Johnson is a defensive healthcare mega-cap delivering 4 consecutive earnings beats while trading at a reasonable 18.8x forward PE. Post-Kenvue spinoff, JNJ is a pure-play pharma/MedTech company with strong oncology growth (Darzalex, Erleada) and expanding MedTech margins. The stock is outperforming SPX (+3.4% vs -1.4%) with ultra-low beta (0.26), offering institutional-grade defensiveness with upside optionality.
Johnson & Johnson is one of the world's largest healthcare companies, operating in two segments: Innovative Medicine (formerly Pharmaceuticals) and MedTech. After spinning off its consumer health business as Kenvue (KVUE) in 2023, JNJ is now a pure-play pharmaceutical and medical technology company.
Key growth drivers include Darzalex (multiple myeloma — blockbuster), Stelara (immunology), Tremfya (psoriasis/IBD — next-gen replacement for Stelara), and Erleada (prostate cancer). The MedTech segment covers orthopedics, surgery, interventional solutions, and vision care. JNJ is a Dividend King with 60+ consecutive years of dividend increases.
| Segment | Revenue | % Total | Description |
|---|---|---|---|
| Innovative Medicine | ~55% | 55% | Oncology (Darzalex, Erleada), Immunology (Stelara, Tremfya), Neuroscience, Cardiovascular |
| MedTech | ~45% | 45% | Orthopedics, Surgery, Interventional Solutions, Vision Care |
| Metric | Value | Signal |
|---|---|---|
| Market Cap | $575.5B | Mega-Cap |
| Trailing P/E | 27.7x | Premium |
| Forward P/E | 18.8x | Fair |
| PEG Ratio | 3.01x | Stretched |
| EV/EBITDA | 17.2x | In-line |
| EV/Revenue | 6.1x | Pharma norm |
| Book Value | $33.74 | P/B 7.09x |
| Beta | 0.26 | Ultra-defensive |
| Dividend Yield | 2.32% | Dividend King |
| Short Interest | 1.08% | Minimal |
| Quarter | EPS Actual | EPS Est. | Surprise | Revenue |
|---|---|---|---|---|
| Q1 2026 | $2.70 | $2.68 | +0.8% | — |
| Q4 2025 | $2.46 | $2.46 | +0% | — |
| Q3 2025 | $2.80 | $2.76 | +1.4% | — |
| Q2 2025 | $2.77 | $2.68 | +3.2% | — |
4/4 consecutive beats — consistent execution with modest surprises typical of large pharma — Next: July 2026 (est.)
| RSI (14) | 59.0 |
| EMA 20 | $232.87 |
| EMA 50 | $231.87 |
| EMA 200 | $213.94 |
| MACD | 1.480 |
| Signal | 1.280 |
| ATR (14) | $5.02 |
Bullish structure with fully aligned EMA stack: EMA20 ($232.87) > EMA50 ($231.87) > EMA200 ($213.94). RSI 58.96 is in healthy neutral-bullish territory with room to run. MACD ($1.48) above signal ($1.28) confirms upward momentum. Extension from EMA20 is only 2.7% — not overstretched. ATR $5.02 (2.1%) provides manageable risk. 52-week high at $251.71 is the next major resistance, currently 5.3% away.
Defensive mega-cap with ultra-low beta and Dividend King status. Primary risks are litigation-related and biosimilar competition, not operational.
JNJ is a defensive mega-cap outperforming the S&P 500 with 4 consecutive earnings beats, ultra-low beta (0.26), and a fully aligned EMA stack. The post-Kenvue pure-play pharma/MedTech focus is driving oncology and rare disease growth. At 18.8x forward PE with a 2.3% dividend yield, the risk/reward favors longs with the 52-week high ($251.71) as the first target.
This analysis is provided for informational and educational purposes only. It does not constitute financial advice, investment recommendation, or solicitation to buy or sell any security.
Past performance is not indicative of future results. All investments involve risk, including the possible loss of principal. Always conduct your own research and consult a licensed financial advisor before making investment decisions.
Data sourced from DailyTickers Gateway, Yahoo Finance, SEC EDGAR, and public market data. Accuracy is not guaranteed.